StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)

Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –

Innoviva cash

Cash and short-term investments held at the end of each period.

Innoviva's cash was $581.39M at Sep 30, 2026. For fiscal 2025 it was $550.94M, up 80.7% from the year before. Over ten years it grew 11.4% a year on average. The highest annual figure on record is $550.94M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$550.94M+80.7%
FY2024Dec 31, 2024$304.96M+57.6%
FY2023Dec 31, 2023$193.51M-33.5%
FY2022Dec 31, 2022$291.05M+44.4%
FY2021Dec 31, 2021$201.53M-18.2%
FY2020Dec 31, 2020$246.49M-29.7%
FY2019Dec 31, 2019$350.85M+205.3%
FY2018Dec 31, 2018$114.91M-11.0%
FY2017Dec 31, 2017$129.08M-14.2%
FY2016Dec 31, 2016$150.43M-19.7%
FY2015Dec 31, 2015$187.28M-22.1%
FY2014Dec 31, 2014$240.50M-48.3%
FY2013Dec 31, 2013$465.13M+87.2%
FY2012Dec 31, 2012$248.49M+3.1%
FY2011Dec 31, 2011$240.92M-22.2%
FY2010Dec 31, 2010$309.63M+551.3%
FY2009Dec 31, 2009$47.54M-48.5%
FY2008Dec 31, 2008$92.28M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$581.39M+22.0%
Q2 FY2026Jun 30, 2026$570.39M+43.5%
Q1 FY2026Mar 31, 2026$603.09M+89.0%
Q4 FY2025Dec 31, 2025$550.94M+80.7%
Q3 FY2025Sep 30, 2025$476.51M+82.8%
Q2 FY2025Jun 30, 2025$397.53M+83.2%
Q1 FY2025Mar 31, 2025$319.09M+78.9%
Q4 FY2024Dec 31, 2024$304.96M+57.6%
Q3 FY2024Sep 30, 2024$260.63M+44.8%
Q2 FY2024Jun 30, 2024$217.00M+25.4%
Q1 FY2024Mar 31, 2024$178.36M+23.8%
Q4 FY2023Dec 31, 2023$193.51M-33.5%
Q3 FY2023Sep 30, 2023$180.00M-40.2%
Q2 FY2023Jun 30, 2023$173.03M-39.0%
Q1 FY2023Mar 31, 2023$144.05M-33.6%
Q4 FY2022Dec 31, 2022$291.05M+44.4%
Q3 FY2022Sep 30, 2022$301.07M+122.8%
Q2 FY2022Jun 30, 2022$283.58M+555.4%
Q1 FY2022Mar 31, 2022$216.80M-23.4%
Q4 FY2021Dec 31, 2021$201.53M-18.2%
Q3 FY2021Sep 30, 2021$135.12M-71.8%
Q2 FY2021Jun 30, 2021$43.27M-89.6%
Q1 FY2021Mar 31, 2021$282.89M-26.3%
Q4 FY2020Dec 31, 2020$246.49M-29.7%
Q3 FY2020Sep 30, 2020$479.19M+61.2%
Q2 FY2020Jun 30, 2020$417.15M+67.1%
Q1 FY2020Mar 31, 2020$383.95M+99.8%
Q4 FY2019Dec 31, 2019$350.85M+205.3%
Q3 FY2019Sep 30, 2019$297.20M+435.7%
Q2 FY2019Jun 30, 2019$249.66M+132.2%
Q1 FY2019Mar 31, 2019$192.18M+240.4%
Q4 FY2018Dec 31, 2018$114.91M-11.0%
Q3 FY2018Sep 30, 2018$55.48M-67.0%
Q2 FY2018Jun 30, 2018$107.54M-20.7%
Q1 FY2018Mar 31, 2018$56.46M-66.8%
Q4 FY2017Dec 31, 2017$129.08M-14.2%
Q3 FY2017Sep 30, 2017$168.19M–
Q2 FY2017Jun 30, 2017$135.63M–
Q1 FY2017Mar 31, 2017$169.81M–
Q4 FY2016Dec 31, 2016$150.43M–

More Innoviva figures

See a number that looks wrong?